April 8, 2020   News/Publications

Critical care and emergency medicine faculty at the LSU Health Shreveport Department of Medicine join the Department of Anesthesia at Massachusetts General Hospital (MGH) and the Division of Cardiology in the Department of Medicine at University of Alabama-Birmingham (UAB) as being among the first centers in the United States to enroll patients in an international study testing using inhaled nitric oxide to improve outcomes for COVID-19 patients with severely damaged lungs; using gas to effectively “kill” coronavirus in the lungs and improve delivery of oxygen to injured tissues.

  April 2, 2020   News/Publications

Scientists in Massachusetts, Italy, and elsewhere are experimenting with a familiar medical treatment for the new problem of covid-19. They’ve begun clinical trials meant to find out whether inhaled nitric oxide can save people who are severely sick from the new coronavirus. This treatment might even be used preventatively to keep health care workers infection-free.

Third Pole Logo

  August 21, 2019   Company Press Releases

Newest Patents Cover Nitric Oxide Generation and Wearable Delivery Systems Arlington, MA – August 21, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems. >> Read …

  July 19, 2019   News/Publications

Each year, roughly 100,000 babies worldwide are diagnosed with a life-threatening condition called persistent pulmonary hypertension of the newborn (PPHN). In infants with PPHN, blood does not circulate properly through the lungs, and sufficient oxygen does not reach the heart, brain and other major organs. Yet, despite the proven effectiveness of inhaled nitric oxide (iNO) as a life-saving treatment for PPHN, access to it by patients has been severely limited—in part because of its expensive, unwieldy system of delivery…

  July 1, 2017   News/Publications

Notice: Following the links below you may be leaving Third Pole Inc.’s website. Third Pole does not imply its endorsement of or concurrence with such information, conclusions or recommendations.
Third Pole Logo

  December 12, 2023   Company Press Releases

– Data from Study Anticipated in Q1 2024 WALTHAM, Mass., December 11, 2023 (GLOBE NEWSWIRE) – Third Pole Therapeutics, Inc., Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, today announced that the first patient has been dosed in an early feasibility study (EFS) performed under an Investigational Device Exemption granted …

Third Pole Logo

  December 14, 2022   Company Press Releases

Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device Waltham, MA –December 14, 2022 – Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are …

Third Pole Logo

  February 3, 2022   Company Press Releases

eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Waltham, MA – February X, 2022 – Third Pole Therapeutics, a privately …

Third Pole Logo

  January 6, 2022   Company Press Releases

WALTHAM, Mass., Jan. 6, 2022 /PRNewswire/ — Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Read More >>

  January 6, 2022   News/Publications

Bill Athenson, CEO of Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, discusses eNOfit™ the company’s proprietary, tankless, on-demand, electrically generated inhaled Nitric Oxide (iNO) technology that is a safe, accurate and reliable lightweight, wearable device that makes iNO from electricity and the air we breathe, creating a make it and take therapy free from the hazards of compressed gas storage.

  October 27, 2021   News/Publications

Last week the hospital marked a significant milestone – the 175th anniversary of the first public demonstration of ether in surgery, considered one of most game-changing events in medical history. In the spirit of that Oct. 16, 1846 landmark, the MGH, fittingly, shares the story of Courtney Joyce, who was the first patient at the hospital to benefit from inhaled …

  February 24, 2021   Company Press Releases

Waltham, MA – February 24, 2021 – Third Pole, Inc., a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced today that it has added two seasoned pharmaceutical executives to its Board of Directors, William Heiden, former CEO and Director of AMAG Pharmaceuticals, and Werner Cautreels, Ph.D., former CEO of Selecta Biosciences. Read More >>

  May 28, 2020   News/Publications

The severity of COVID-19 respiratory failure in some patients has taken the medical community by surprise. And in response, that community has been trying just about anything that seems reasonable in an effort to improve outcomes — and in some cases as last-resort measures to save lives.

Promising Prototypes to Watch in 2018

Engineering for Change

  December 29, 2017   News/Publications

The technologies that improve lives in the world’s underserved communities are born as prototypes that evolve through testing and tinkering in workshops, laboratories and garages…

  May 1, 2014   News/Publications

In the 25 years since discovering a life-saving therapy consisting of breathing low levels of the gas nitric oxide—which is still the only selective inhaled pulmonary vasodilator—Massachusetts General Hospital (MGH) anesthesiologist Warren M. Zapol, MD, and his MGH team has given clinicians a treatment to simply save the lives of vast numbers of hypoxic newborns (“blue babies”)and prevent or reverse pulmonary hypertension in hundreds of thousands of adults during surgery…